Autologous dendritic cell vaccine

This page covers all Autologous dendritic cell vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Breast cancer-associated antigens (patient-specific).

Targets

Breast cancer-associated antigens (patient-specific)

Phase 3 pipeline (2)

• AV-GBM-1 · Aivita Biomedical, Inc. · Oncology
  AV-GBM-1 is an autologous dendritic cell vaccine designed to stimulate the patient's immune system to recognize and attack glioblastoma tumor cells.
• SV-BR-1-GM · BriaCell Therapeutics Corporation · Oncology
  SV-BR-1-GM is an autologous breast cancer immunotherapy that uses patient-derived dendritic cells loaded with breast cancer-associated antigens to stimulate anti-tumor immune responses.